News

Press Release Issued:
IASIC Opposes the Removal of Cannabis from Schedule 1

BURLINGTON, Vermont – June 25, 2024 – The International Academy on the Science and Impact of Cannabis (IASIC) released its official statement against the proposed rescheduling of Cannabis from Schedule I to Schedule III of the Controlled Substances Act:

As physicians and concerned citizens of the United States of America, the International Academy on the Science and Impact of Cannabis believes that re-scheduling will have immediate and irreparable harm to the public health and vehemently oppose the removal of cannabis from Schedule 1. Specific objections include (1) The Department of Health and Human Services (HHS) inappropriately changed the definition of currently acceptable medical use (CAMU); (2) Even under the new definition, cannabis still does not meet the requirements for CAMU; (3) Proper regulation of cannabis as a schedule 3 drug cannot be achieved while non-medical cannabis commerce is allowed.

“HHS and those who are pushing rescheduling of cannabis are unaware or ignoring the huge amount of science on the medical harms of cannabis. There is zero benefit and only problems to be had from rescheduling,” said Eric A. Voth, MD, FACP, President and Chairman of the Board, The International Academy on the Science and Impact of Cannabis.

An official request for a hearing with the DEA has been submitted by IASIC during the current open comment period, with its leadership urging the presentation of medical and scientific research from its physician-driven organization of international experts on cannabis.

IASIC has provided substantial education and background on the impending harm of the proposed rescheduling in its monthly speaker series on June 11th as well as on the High Truths on Drugs and Addiction podcast with episode #182: High Truths on Drugs and Addiction on Rescheduling of Marijuana with IASIC.

Association of Mandatory Warning Signs for Cannabis Use During Pregnancy With Cannabis Use Beliefs and Behaviors

July 6, 2023 No Comments

Question Are policies mandating warning signs regarding the harms of cannabis use during pregnancy associated with beliefs and behaviors? Findings This cross-sectional study used data from 2063 US-based survey respondents who were or had recently been pregnant and found that, among people who used cannabis during pregnancy, living in a state with a warning signs

Read More »

Associations Between Prenatal Cannabis Exposure and Childhood Outcomes

July 6, 2023 No Comments

Question Is prenatal exposure to cannabis associated with child outcomes? Findings This cross-sectional analysis of 11 489 children (655 exposed to cannabis prenatally) found that prenatal cannabis exposure after maternal knowledge of pregnancy was associated with greater psychopathology during middle childhood, even after accounting for potentially confounding variables. Meaning Prenatal cannabis exposure may increase risk for

Read More »

Characteristics Associated With Cannabis Use Initiation by Late Childhood and Early Adolescence the Adolescent Brain Cognitive Development(ABCD) Study

July 6, 2023 No Comments

Early-onset cannabis use is common (eg, 12% of 14- to 15-year-olds in the US report lifetime use) and is associated with increased risk for cannabis use disorder, other psychiatric disorders, and other problems (eg, early school drop-out) during childhood and adulthood.1,2 Prospective risk factors of early-onset cannabis use remain poorly understood. Methods | Participants provided

Read More »

On offer to Ontario consumers three years after legalization: A profile of cannabis Products, cannabinoid content, plant type, and prices

July 6, 2023 No Comments

Introduction: Cannabis was legalized in Canada in October 2018, regulating theproduction, distribution, sale, and possession of dried cannabis and cannabis oils.Additional products were legalized 1 year later, including edibles, concentrates,and topicals, with new lines of commercial products coming to market. Ontario isthe most populous province in Canada and has the largest cannabis market withthe highest

Read More »

Effects of U.S. State Medical Cannabis Laws on Treatment of Chronic Non cancer Pain

July 6, 2023 No Comments

Background: State medical cannabis laws may lead patients with chronic noncancer pain to substitute cannabis in place ofprescription opioid or clinical guideline-concordant nonopioid prescription pain medications or procedures. Objective: To assess the effects of state medical cannabis laws on the receipt of prescription opioids, nonopioid prescription painmedications, and procedures for chronic noncancer pain. Design: Using

Read More »

Overuse of marijuana linked to surgery complications and death, study says

July 6, 2023 No Comments

Clinical overuse of marijuana is linked to a variety of complications after major elective surgery, including blood clots, stroke, breathing difficulties, kidney issues, and even death, a new study found. Using marijuana may affect your ability to think and plan, study says “Our findings complement previous studies that have identified significant associations between cannabis use disorders and perioperative complications,”

Read More »

First Medical Textbook on Cannabis in Medicine

Listen to podcast High Truths on Drugs and Addiction on your favorite platform. ​Hightruth.com

Most Recent News

Libby Stuyt Interview on Randy Tobler show

Exciting News! Libby Stuyt’s Interview on Randy Tobler Show! Hey everyone, we wanted to share some thrilling news! The brilliant Dr. Libby Stuyt recently had an enlightening interview on Randy Tobler Show. Dr. Stuyt is known for her groundbreaking work in the field of addiction medicine and mental health. Her insights are nothing short of

Read More »

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Introduction Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol and cannabidiol are the most clinically relevant. Tetrahydrocannabinol is a partial agonist at CB1 and binds CB2 receptors. CB1 is widely expressed by central and peripheral neurones but also by immune cells and other type of cells in the brain and in the periphery, and when

Read More »

IASIC Speaker Series Presents: Case Report on Cannabis-Induced Acute Encephalopathy in Elderly After Taking CBD

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Read More »
Scroll to Top